Ensysce Biosciences secured a $4 million convertible preferred stock financing.
Up to $16 million additional funding may be unlocked through future tranches.
Funding will support Phase 3 clinical development of PF614 and innovation in abuse- and overdose-resistant analgesics.
Funding Flexibility
$16 million available for critical programs.
Phase 3 Acceleration
PF614 clinical trials moving towards market readiness within 18-24 months.
Investor Confidence
Backers continue to support Ensysce's mission-driven innovation.
- The financing will accelerate the Phase 3 clinical program for PF614.
- Ensysce's vision of safe and effective analgesics is supported by strong investor confidence.
- The funding will aid in delivering transformative treatments for patients with severe pain.
Ensysce Biosciences' financing demonstrates strong investor confidence and paves the way for innovative pain management solutions.